This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: March 30th, 2010 - March 30th, 2011
This activity was developed for pharmacy directors, P&T Committee members, managed care pharmacists, oncology pharmacists, and other key stakeholders who wish to enhance their practical insight on the health system/regional variances in the delivery of care for multiple myeloma.
At the completion of this activity participants should be able to:
- Identify the intersection of epidemiologic shifts in the multiple myeloma patient population, including new diagnostic measures, staging, and achieving value-based clinical treatment strategies
- Discuss the treatment of the newly diagnosed patient, including review of appropriate agent selection based on recently presented clinical trials
- Describe treatment strategies in the relapsed patient, including the improvement in survival in the maintenance setting
- Examine regional/health system variations in healthcare delivery, including diagnosing, treatment, and coverage decisions for the patient with multiple myeloma
Registered Pharmacy Designation
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 2.0 contact hours (0.2 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-10-019-H01-P.
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakerâ€™s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.
The associates of Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.
Gary M. Owens, MD, is a Consultant to Asthmatx, Biosense Webster, Centocor-OrthoBiotech, Eli Lilly, Genentech, and Novartis.
Jatin Shah, MD is a consultant for Amgen, Celgene, and Millennium, and is on an advisory board for Novartis .
Rusty Crawford, RPh, BCOP has nothing to disclose.
Sin (Masha) Lam, PharmD, BCOP has nothing to disclose.
Stephanie Taber, PharmD, BCOP has nothing to disclose.
*Content will include non-FDA-approved uses.
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.